• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    8/1/23 9:06:23 AM ET
    $ABVC
    $AGLE
    $AMPE
    $CELZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

    Gainers

    • ABVC BioPharma (NASDAQ:ABVC) shares moved upwards by 92.0% to $4.78 during Tuesday's pre-market session. The market value of their outstanding shares is at $15.8 million.
    • Ampio Pharmaceuticals (AMEX:AMPE) stock increased by 17.29% to $0.27. The company's market cap stands at $4.1 million.
    • EQRx (NASDAQ:EQRX) stock increased by 15.78% to $1.98. The market value of their outstanding shares is at $964.9 million.
    • Cadrenal Therapeutics (NASDAQ:CVKD) stock moved upwards by 14.11% to $0.97. The company's market cap stands at $12.6 million.
    • Creative Medical Tech (NASDAQ:CELZ) stock increased by 13.56% to $6.26. The market value of their outstanding shares is at $8.8 million.
    • Vapotherm (NYSE:VAPO) shares rose 10.52% to $0.42. The market value of their outstanding shares is at $19.4 million.

    Losers

    • TG Therapeutics (NASDAQ:TGTX) shares fell 38.2% to $12.79 during Tuesday's pre-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out today.
    • OKYO Pharma (NASDAQ:OKYO) stock declined by 19.26% to $1.51. The market value of their outstanding shares is at $38.5 million.
    • Mallinckrodt (AMEX:MNK) shares fell 14.82% to $1.38. The company's market cap stands at $18.1 million.
    • Revolution Medicines (NASDAQ:RVMD) stock fell 12.39% to $23.0. The company's market cap stands at $2.4 billion.
    • Aeglea BioTherapeutics (NASDAQ:AGLE) stock fell 9.76% to $0.51. The market value of their outstanding shares is at $39.9 million.
    • Trevi Therapeutics (NASDAQ:TRVI) stock fell 9.25% to $2.16. The market value of their outstanding shares is at $129.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $AGLE
    $AMPE
    $CELZ

    CompanyDatePrice TargetRatingAnalyst
    Revolution Medicines Inc.
    $RVMD
    2/27/2026$145.00Buy
    UBS
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    OKYO Pharma Limited
    $OKYO
    12/8/2025$5.00Buy
    B. Riley Securities
    Revolution Medicines Inc.
    $RVMD
    11/18/2025$75.00Outperform
    Wolfe Research
    Trevi Therapeutics Inc.
    $TRVI
    11/13/2025$13.00Outperform
    Leerink Partners
    Revolution Medicines Inc.
    $RVMD
    11/3/2025$77.00Outperform
    RBC Capital Mkts
    Revolution Medicines Inc.
    $RVMD
    10/21/2025$90.00Outperform
    Mizuho
    Revolution Medicines Inc.
    $RVMD
    10/16/2025$85.00Buy
    Stifel
    More analyst ratings

    $ABVC
    $AGLE
    $AMPE
    $CELZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    12/9/24 4:15:16 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arnerich Anthony L. bought $117,337 worth of shares (37,750 units at $3.11), increasing direct ownership by 263% to 24,509 units (SEC Form 4) (Amendment)

    4/A - VAPOTHERM INC (0001253176) (Issuer)

    10/4/23 4:11:34 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Brancaccio John P bought $25,005 worth of Ordinary Shares (16,670 units at $1.50) (SEC Form 4)

    4 - OKYO Pharma Ltd (0001849296) (Issuer)

    9/28/23 6:15:12 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $AGLE
    $AMPE
    $CELZ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for UKONIQ

    Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

    2/9/21 12:05:59 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AGLE
    $AMPE
    $CELZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Anderson Elizabeth M received a gift of 15,000 shares and gifted 15,000 shares, decreasing direct ownership by 65% to 8,215 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    3/6/26 6:20:31 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Wang Xiaolin was granted 15,100 shares, increasing direct ownership by 15% to 118,073 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    3/3/26 9:11:14 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Wei Lin was granted 15,100 shares, increasing direct ownership by 17% to 103,439 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    3/3/26 9:10:30 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $AGLE
    $AMPE
    $CELZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

    NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2026 annual meeting, being held April 18 - 22, 2026, in Chicago, Illinois. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. Details of the upcoming presentations are outlined below. TG PRESENTATIONS: Poster Presentation Title: Real World Clinical Experience from ENABLE, the First Phase 4 Observational Study for Patien

    3/6/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

    Encouraging data for CAD-1005 in Phase 2 HIT Study  EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic disorders, today provided additional perspectives on development opportunities following its recent pipeline expansion with the addition of 12-LOX inhibitors. As previously announced, Cadrenal recently acquired a portfolio of selective 12-LOX inhibitors, including oral candidates. Encouraging recent data from a bli

    3/2/26 8:00:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics to Participate in Upcoming March Conferences

    NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in March. Leerink Partners 2026 Global Healthcare ConferenceMarch 8 – 11, 2026, Miami, FloridaFireside Chat: March 11, 8:40 a.m. ETTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDORegister h

    3/2/26 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AGLE
    $AMPE
    $CELZ
    SEC Filings

    View All

    SEC Form DEF 14A filed by ABVC BioPharma Inc.

    DEF 14A - ABVC BIOPHARMA, INC. (0001173313) (Filer)

    3/5/26 4:29:58 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 10-Q/A filed by ABVC BioPharma Inc.

    10-Q/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)

    3/3/26 4:19:07 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by ABVC BioPharma Inc.

    10-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)

    3/3/26 4:20:35 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AGLE
    $AMPE
    $CELZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Revolution Medicines with a new price target

    UBS resumed coverage of Revolution Medicines with a rating of Buy and set a new price target of $145.00

    2/27/26 8:31:41 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on OKYO Pharma with a new price target

    B. Riley Securities initiated coverage of OKYO Pharma with a rating of Buy and set a new price target of $5.00

    12/8/25 8:35:27 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $AGLE
    $AMPE
    $CELZ
    Financials

    Live finance-specific insights

    View All

    TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

    Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately $875-900 million in total global revenue for 2026 Conference call to be held today, Thursday, February 26, 2026, at 8:30 AM ET NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2025, along with recent company developments and 2026 financial guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Off

    2/26/26 7:00:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

    On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three additional Phase 3 trials planned to initiate in 2026Expects to substantially complete enrollment in RASolve 301, a Phase 3 trial of daraxonrasib in previously treated NSCLC, this yearInitiated RASolute 305, the first Phase 3 trial for zoldonrasib, in first line metastatic PDAC harboring a RAS G12D mutationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-s

    2/25/26 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.

    2/23/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AGLE
    $AMPE
    $CELZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.

    SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

    11/14/24 7:45:34 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

    SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

    11/14/24 7:33:18 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/14/24 5:51:58 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AGLE
    $AMPE
    $CELZ
    Leadership Updates

    Live Leadership Updates

    View All

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer

    Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announces that, effective immediately, Robert J. Dempsey will assume the role of Chief Executive Officer. Gary S. Jacob, Ph.D. will transition to Chief Development Officer and

    1/5/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

    Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective January 6, 2026.  www.trevitherapeutics.com (PRNewsfoto/Trevi

    12/4/25 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care